Novel Anti-Inflammatory High-CBD Marijuana Modulate ACE2 Expression in Covid-19

Preprint
Article
Variation 1
This variation is not peer-reviewed

Version 1.
: Gotten: 17 April 2020/ Authorized: 19 April 2020/ Online: 19 April 2020 (02: 45: 50 CEST).

Wang, B.; Kovalchuk, A.; Li, D.; Ilnytskyy, Y.; Kovalchuk, I.; Kovalchuk, O. Searching For Preventative Strategies: Novel Anti-Inflammatory High-CBD Cannabis Sativa Extracts Modulate ACE2 Expression in COVID-19 Gateway Tissues. Preprints2020, 2020040315 (doi: 10.20944/ preprints2020040315 v1).

Wang, B.; Kovalchuk, A.; Li, D.; Ilnytskyy, Y.; Kovalchuk, I.; Kovalchuk, O. In Search of Preventative Strategies: Unique Anti-Inflammatory High-CBD Cannabis Sativa Extracts Regulate ACE2 Expression in COVID-19 Gateway Tissues.

.

Abstract

It utilizes receptor-mediated entry into the human host by means of angiotensin-converting enzyme II (ACE2) that is revealed in lung tissue, as well as oral and nasal mucosa, kidney, testes, and the intestinal tract. Working under the Health Canada research study license, we have established over 800 brand-new Marijuana sativa lines and extracts and hypothesized that high-CBD C. sativa extracts may be utilized to regulate ACE2 expression in COVID-19 target tissues. Evaluating C. sativa extracts using synthetic human 3D designs of oral, airway, and digestive tract tissues, we identified 13 high CBD C. sativa extracts that regulate ACE2 gene expression and ACE2 protein levels.

Subject Areas

COVID-19; SARS-CoV2; ACE2 receptor; medical marijuana; CBD.

This is an open access article dispersed under the Creative Commons Attribution License which permits unlimited usage, circulation, and recreation in any medium, supplied the original work is effectively cited.

Comments (8 )

We motivate remarks and feedback from a broad range of readers. See criteria for comments and our diversity declaration.

Leave a public remark
Send out a personal comment to the author( s)

Learn more